Analyst Activity – Barclays Raises Its Price Target On Myriad Genetics (NASDAQ:MYGN) to $35.00

Analyst Ratings For Myriad Genetics (NASDAQ:MYGN)

Story continues below

Today, Barclays raised its price target on Myriad Genetics (NASDAQ:MYGN) to $35.00 per share.

Some recent analyst ratings include

  • 10/2/2017-Leerink Swann Reiterated Rating of Mkt Perform .
  • 9/17/2017-Cowen Reiterated Rating of Hold.


  • On 1/18/2018 Gary A King, VP, sold 3,120 with an average share price of $38.12 per share and the total transaction amounting to $118,934.40.
  • On 1/12/2018 Richard M Marsh, VP, sold 13,759 with an average share price of $36.25 per share and the total transaction amounting to $498,763.75.
  • On 12/14/2017 Walter Phd Gilbert, Director, sold 7,500 with an average share price of $33.19 per share and the total transaction amounting to $248,925.00.
  • On 12/11/2017 Heinrich Dreismann, Director, sold 6,000 with an average share price of $33.50 per share and the total transaction amounting to $201,000.00.
  • On 11/13/2017 Alexander Ford, Insider, sold 3,031 with an average share price of $31.64 per share and the total transaction amounting to $95,900.84.
  • On 9/1/2017 John T Henderson, Director, sold 30,000 with an average share price of $30.30 per share and the total transaction amounting to $909,000.00.
  • On 2/23/2017 John T Henderson, Director, bought 6,000 with an average share price of $18.66 per share and the total transaction amounting to $111,960.00.

Recent Trading Activity for Myriad Genetics (NASDAQ:MYGN)
Shares of Myriad Genetics closed the previous trading session at 39.85 up +1.23 3.18% with 38.47999954223633 shares trading hands.

An ad to help with our costs